Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by J.P. Marvel Investment Advisors LLC

J.P. Marvel Investment Advisors LLC lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 4.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,604 shares of the medical research company's stock after selling 1,827 shares during the quarter. Charles River Laboratories International makes up about 1.1% of J.P. Marvel Investment Advisors LLC's holdings, making the stock its 24th biggest position. J.P. Marvel Investment Advisors LLC owned 0.07% of Charles River Laboratories International worth $6,942,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Wellington Management Group LLP boosted its position in shares of Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the period. State Street Corp boosted its holdings in shares of Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after acquiring an additional 41,421 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after acquiring an additional 47,221 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Charles River Laboratories International by 6.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company's stock valued at $101,483,000 after acquiring an additional 32,311 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after purchasing an additional 85,759 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. JPMorgan Chase & Co. reduced their price objective on Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating for the company in a research note on Monday, February 3rd. Barclays lowered their target price on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a research note on Tuesday. StockNews.com cut Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. Finally, UBS Group reiterated a "neutral" rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $197.64.

Charles River Laboratories International Trading Up 6.9 %

Shares of CRL stock traded up $10.61 during mid-day trading on Wednesday, hitting $165.00. 1,983,081 shares of the company's stock were exchanged, compared to its average volume of 1,032,290. The stock has a market cap of $8.44 billion, a price-to-earnings ratio of 20.65, a PEG ratio of 5.91 and a beta of 1.37. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $275.00. The stock has a 50-day simple moving average of $174.02 and a two-hundred day simple moving average of $188.99.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.46 earnings per share. Equities analysts expect that Charles River Laboratories International, Inc. will post 10.16 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).